Trevi Therapeutics Inc $ 3.09 -0.01 (-0.16%)
Warning! GuruFocus has detected with TRVI. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Trevi Therapeutics Inc () from 2019 to Nov 29 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Trevi Therapeutics stock (TRVI) PE ratio as of Nov 29 2020 is 0. More Details
Trevi Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Trevi Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:ONCT NAS:ZSAN NAS:CLDX NAS:SEEL NAS:COCP NAS:SNSS NAS:VBLT OTCPK:GNBT OTCPK:IPIX NAS:SAVA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Traded in other countries TRVI.USA
Address 195 Church Street, 14th Floor, New Haven, CT, USA, 06510
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.